(S034) Frequency of Whole-Breast Radiation Therapy Following Intraoperative Radiation Therapy Due to Criteria Identified by Lumpectomy

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Using these criteria, about 6% of patients preoperatively meeting no ASTRO APBI consensus cautionary or unsuitable risk factors are recommended for WBRT after IORT. This rate is much higher for patients meeting cautionary criteria before resection.

Eric A. Mellon, MD, PhD, Luis E. Joya, Amber Orman, MD, Michael E. Montejo, MD, Christine Laronga, MD, Marie C. Lee, MD, Susan J. Hoover, MD, Nazanin Khakpour, MD, Pamela F. Kubal, ARNP, Roberto Diaz, MD, PhD; H. Lee Moffitt Cancer Center and Research Institute

PURPOSE: For low-risk early breast cancers, intraoperative radiation therapy (IORT) can be an efficient alternative to fractionated whole-breast RT (WBRT). However, some patients are recommended for WBRT after IORT due to postoperative pathologic findings.

METHODS: A single-institution retrospective chart review of all nonrecurrent IORT cases (20 Gy to the tumor cavity using a 50-kV photon applicator) treated between January 2011 and October 2015 was performed to identify patients who subsequently received WBRT. Eligibility at our institution for accelerated partial breast irradiation (APBI) is based on the 2009 Consensus Statement from the American Society for Radiation Oncology (ASTRO). We offered IORT as the sole radiation therapy modality to patients meeting 0–1 “cautionary” criteria and no “unsuitable” criteria prior to lumpectomy. WBRT was recommended following IORT when ≥ 2 cautionary and/or ≥ 1 unsuitable criteria were met after accounting for resection pathology or per physician or patient preference. Margin status allowed for re-resections to clear margins.

RESULTS: There were 161 IORT patients; 15 (9%) patients required WBRT. Of those, 3 of 15 patients elected not to receive WBRT. An additional 10 patients received WBRT due to patient or physician preference (for 22 recipients of WBRT, or 14% of the patient population). Prior to resection, 19 of 161 (12%) patients met one cautionary criterion. Of those, additional criteria were assigned to 7 of 19 (37%) based on final pathology prompting a recommendation of WBRT. In total, 41 of 161 (25%) patients were assigned ≥ 1 cautionary or unsuitable criterion from resection pathology. Of 11 patients aged 50–60 years, 6 (55%) were recommended for WBRT. Only 8 of 142 (6%) patients with no criteria preoperatively gained ≥ 2 unsuitable criteria or ≥ 1 cautionary criterion on final analysis.

CONCLUSION: Using these criteria, about 6% of patients preoperatively meeting no ASTRO APBI consensus cautionary or unsuitable risk factors are recommended for WBRT after IORT. This rate is much higher for patients meeting cautionary criteria before resection.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content